Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1290779 | 0.83 | VNN1 (0.38) | CYP2D6VNN1FFAR3 | |
| SCHEMBL346031 | 0.82 | CHRM2 (0.43) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2202122 | 0.79 | NPC1 (0.33) | — | |
| SCHEMBL4980253 | 0.79 | USP2 (0.38) | USP2CYP4F2CYP4A11 | |
| SCHEMBL16113435 | 0.78 | — | — | |
| SCHEMBL18044505 | 0.78 | KMT2A (0.35) | USP2FFAR3 | |
| SCHEMBL1317472 | 0.78 | PTPN11 (0.33) | CHRM2CHRM1CHRM3USP2FFAR3 | |
| SCHEMBL20484883 | 0.78 | VNN1 (0.35) | CYP3A4CYP2D6USP2VNN1FFAR3 | |
| SCHEMBL238639 | 0.78 | PKLR (0.34) | — | |
| SCHEMBL1993718 | 0.76 | PTPN11 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710975-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2019-06-20 | — | — | US | disclosed |
| CN-101006057-A | Novel piperidine/8-azabicyclo [3.2.1] octan derivatives as moduilators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2007-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710975-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | CHRM2 1155/4885CHRM1 778/4885CHRM3 743/4885 |
| US-20190185449-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | CHRM2 1155/4885CHRM1 778/4885CHRM3 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.